BridgeBio Pharma, Inc.
BBIO
Classifica tra le azioni
#1619
BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying,... BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying, advancing, and providing medical solutions for various genetic conditions. The firm boasts an extensive portfolio comprising 30 distinct development initiatives, spanning the entire spectrum from initial discovery research to advanced clinical trial phases. Notable candidates within its development pipeline include: AG10 and BBP-265: A small molecule designed to stabilize transthyretin (TTR), currently in a pivotal Phase 3 clinical trial targeting transthyretin amyloidosis-cardiomyopathy (ATTR-CM). BBP-831: A selective small molecule inhibitor of FGFR1-3, which is undergoing Phase 2 clinical evaluation for treating achondroplasia in pediatric patients. BBP-631: An AAV5 gene transfer product candidate, also in Phase 2 clinical trials, aimed at congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency (21OHD). Furthermore, BridgeBio is developing: Encaleret: A small molecule antagonist of the calcium sensing receptor (CaSR), presently in a Phase 2 proof-of-concept study for Autosomal Dominant Hypocalcemia Type 1 (ADH1). BBP-711: Intended for the management of hyperoxaluria and individuals prone to recurring kidney stones. Beyond these specific programs, the company is actively engaged in developing therapies for a broader range of Mendelian disorders, oncological diseases, and gene therapy applications. BridgeBio Pharma, Inc. maintains strategic licensing and collaboration agreements with institutions such as Leland Stanford Junior University, The Regents of the University of California, and Leidos Biomedical Research, Inc. Established in 2015, the company's corporate headquarters are situated in Palo Alto, California.
Prezzo delle azioni
$67.94
Capitalizzazione di mercato
$13.28B
Variazione (1 giorno)
0.00%
Variazione (1 anno)
20.76%
Paese
US
Scambia BridgeBio Pharma, Inc. (BBIO)
Categoria
Healthcare
Ricavi di BridgeBio Pharma, Inc. (BBIO)
Ricavi nel Jun 2026 TTM: $713.07M
Secondo gli ultimi rapporti finanziari di BridgeBio Pharma, Inc., i ricavi attuali dell'azienda (TTM) sono pari a $713.07M. Nel 2023, l'azienda ha registrato ricavi di $9.30M una diminuzione rispetto a i ricavi dell'anno 2022, che erano pari a $77.65M. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per BridgeBio Pharma, Inc. da 2017 a 2026
Ricavi alla fine di ogni anno
| Anno | Ricavi | Cambia |
|---|---|---|
| 2026 (TTM) | $713.07M | 221.35% |
| 2024 | $221.90M | 2,285.27% |
| 2023 | $9.30M | -88.02% |
| 2022 | $77.65M | 11.38% |
| 2021 | $69.72M | 745.14% |
| 2020 | $8.25M | -79.66% |
| 2019 | $40.56M | 0.00% |
| 2018 | 0.00 | 0.00% |
| 2017 | 0.00 | 0.00% |
Ricavi di aziende simili o concorrenti
| Azienda | Ricavi | Differenza nei ricavi | Il paese |
|---|---|---|---|
| $12.62B | 1,670.41% |
US
|
|
| $2.23B | 212.45% |
US
|
|
| $15.74B | 2,107.96% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 744.42% |
NL
|
